Sven Stodtmann

Ludwigshafen Am Rhein, RP, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Extrapolating Efficacy of Cariprazine to Pediatric Schizophrenia and Bipolar Mania Through Population Pharmacokinetic Analysis.

Extrapolating Efficacy of Cariprazine to Pediatric Schizophrenia and Bipolar Mania Through Population Pharmacokinetic Analysis.

Journal: Journal of clinical pharmacology

Published: April 16, 2026

Population Pharmacokinetics and Exposure-Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1-3 Studies.

Population Pharmacokinetics and Exposure-Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1-3 Studies.

Journal: Journal of clinical pharmacology

Published: December 16, 2025

Exposure-Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine.

Exposure-Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine.

Journal: CPT: pharmacometrics & systems pharmacology

Published: August 22, 2025

Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices.

Predictive AI in Clinical Pharmacology: A Call to Action to Develop Robust Benchmarking Practices.

Journal: CPT: pharmacometrics & systems pharmacology

Published: July 21, 2025

Population Pharmacokinetics of Atogepant for the Prevention of Migraine.

Population Pharmacokinetics of Atogepant for the Prevention of Migraine.

Journal: Clinical pharmacokinetics

Published: May 13, 2025

Model-Informed Paradigm in Drug Development-An End-To-End Case Study From Upadacitinib Development.

Model-Informed Paradigm in Drug Development-An End-To-End Case Study From Upadacitinib Development.

Journal: Clinical and translational science

Published: March 31, 2025

Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.

Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials.

Journal: Cephalalgia : an international journal of headache

Published: February 21, 2025

Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's Disease.

Use of Model-Based Meta-Analysis to Inform the Design of Early Clinical Trials of Anti-Amyloid Beta Therapies in Alzheimer's Disease.

Journal: CPT: pharmacometrics & systems pharmacology

Published: December 02, 2024

Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development.

Practical guide to SHAP analysis: Explaining supervised machine learning model predictions in drug development.

Journal: Clinical and translational science

Published: August 14, 2024

Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure-Response Models, and Real-World Patient Data.

Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure-Response Models, and Real-World Patient Data.

Journal: Clinical pharmacology and therapeutics

Published: April 11, 2024

SERENE ER Analysis Part 1-SERENE CD: Exposure-Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease.

SERENE ER Analysis Part 1-SERENE CD: Exposure-Response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients With Moderately to Severely Active Crohn Disease.

Journal: Clinical pharmacology in drug development

Published: February 08, 2024

SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis.

SERENE ER Analysis Part 2 SERENE-UC: Exposure-response Analysis of Higher Versus Standard Adalimumab Dosing Regimens for Patients with Moderately to Severely Active Ulcerative Colitis.

Journal: Clinical pharmacology in drug development

Published: February 08, 2024

Showing 1-12 of 28

Last Updated: 09/26/2026